Ethical issues and reflections on clinical research of radiopharmaceuticals
10.12026/j.issn.1001-8565.2025.02.17
- VernacularTitle:放射性药物临床研究的伦理问题及思考
- Author:
Yonglan HU
1
;
Li WANG
2
;
Feng JIANG
3
;
Jiyin ZHOU
4
;
Zhengjun CHEN
5
;
Jie ZHANG
5
;
Zengrui ZHANG
5
Author Information
1. Department of Scientific Research and Teaching， Xuyong People’s Hospital， Luzhou 646000， China
2. Sichuan Key Laboratory of Nuclear Medicine and Molecular Imaging， Luzhou 646000， China
3. National Drug Clinical Trial Institution， the Affiliated Hospital of Southwest Medical University， Luzhou 646000， China
4. Clinical Medical Research Center， the Second Affiliated Hospital of Army Military Medical University， Chongqing 400037， China
5. Clinical Trial Ethics Committee， the Affiliated Hospital of Southwest Medical University， Luzhou 646000， China
- Publication Type:Journal Article
- Keywords:
radiopharmaceutical;
clinical research;
ethical review
- From:
Chinese Medical Ethics
2025;38(2):254-260
- CountryChina
- Language:Chinese
-
Abstract:
Radiopharmaceuticals play an important role in the diagnosis and treatment of cardiovascular and cerebrovascular diseases， malignant tumors， central nervous system diseases， and other diseases. Under the urgent need for clinical diagnosis and treatment as well as medical development， the clinical research of radiopharmaceuticals has become a hotspot in international research. By analyzing the current situation of clinical research on radiopharmaceuticals in Europe， America， and China， the ethical issues of clinical research on radiopharmaceuticals were elaborated from four aspects， including lack of relevant laws and regulations， a higher risk of radiopharmaceuticals， dilemmas in ethical review， and insufficient radiation protection. Response principles and measures were proposed from four aspects， including improving regulations and policies， enhancing radiological protection for all parties involved in the research， strengthening ethical review， and reinforcing the training of relevant personnel， to enhance the quality and level of clinical research on radiopharmaceuticals.
